A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Schreiber, Stefan; Rutgeerts, Paul; Fedorak, Richard N.; Khaliq-Kareemi, Munaa; Kamm, Michael A.; Boivin, Michel; Bernstein, Çharles N.; Staun, Michael; Thomsen, Ole Østergaard; Innes, Alison

doi:10.1053/j.gastro.2005.06.064

Cited by 534 publications

(373 citation statements)

References 30 publications

Supporting

Mentioning

351

Contrasting

Unclassified

Order By: Relevance

“…18,19,31,32 In the present study, the First exposure group received CZP on a maintenance schedule during PRECiSE 3 without a CZP induction regimen. This group did not fare as well as the Re-exposure and Continuous exposure groups over long-term treatment.…”

Section: Discussionmentioning

confidence: 99%

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Sandborn

Lee

Randall

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Sandborn

Lee

Randall

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Since the first double-blind, placebo-controlled trial with Infliximab (IFX) 2 numerous pivotal trials on the efficacy of IFX, Adalimumab (ADA) and Certzolizumab pegol (CTZ) in inducing and maintaining clinical response and remission and achieving mucosal healing have been published [2][3][4][5][6][7] .…”

Section: Introductionmentioning

confidence: 99%

Addressing current treatment challenges in Crohn's disease in real life: A physician's survey

Vavricka

Radivojevic²,

Manser³

et al. 2014

Digestive and Liver Disease

View full text Add to dashboard Cite

BACKGROUND: In recent years several trials have addressed treatment challenges in Crohn's disease. Clinical trials however, represent a very special situation. AIMS: To perform a cross-sectional survey among gastroenterologists on the current clinical real life therapeutic approach focussing on the use of biologics. METHODS: A survey including six main questions on clinical management of loss of response, diagnostic evaluation prior to major treatment changes, preference for anti-tumour necrosis factor (TNF) agent, (de-)escalation strategies as well as a basic section regarding personal information was sent by mail to all gastroenterologists in Switzerland (n=318). RESULTS: In total, 120 questionnaires were analysed (response rate 37.7%). 90% of gastroenterologists in Switzerland use a thiopurine as the first step-up strategy (anti-TNF alone 7.5%, combination 2.5%). To address loss of response, most physicians prefer shortening the interval of anti-TNF administration followed by dose increase, switching the biologic and adding a thiopurine. In case of prolonged remission on combination therapy, the thiopurine is stopped first (52.6%) after a mean treatment duration of 15.7 months (biologic first in 41.4%). CONCLUSIONS: Everyday clinical practice in Crohn's disease patients appears to be incongruent with clinical data derived from major trials. Studies investigating reasons underlying these discrepancies are of need to optimize and harmonize treatment.

show abstract

“…The efficacy of CZP in patients with Crohn's disease has previously been demonstrated in a number of clinical studies. [12][13][14] Results from the PRECiSE 2 study have been fully published elsewhere 13 and demonstrated that compared with placebo significantly more patients with moderate-to-severe Crohn's disease treated with CZP maintained response and remission at week 26 following open-label induction therapy.…”

mentioning

confidence: 99%

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

Hanauer

Panés

Colombel

et al. 2010

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Cited by 534 publications

References 30 publications

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Addressing current treatment challenges in Crohn's disease in real life: A physician's survey

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

Contact Info

Product

Resources

About